Comment le cannabis et la psilocybine pourraient-ils aider une partie des 50 millions d'Américains qui souffrent de douleurs chroniques ?

L'évolution des attitudes et des cadres réglementaires concernant le cannabis et la psilocybine aux États-Unis pourrait ouvrir la voie à des approches novatrices en matière de gestion de la douleur. Pour en savoir plus, en anglais, veuillez lire les informations ci-dessous.

The U.S. Drug Enforcement Agency announced in late April 2024 that it plans to ease federal restrictions on cannabis, reclassifying it from a Schedule I drug to the less restricted Schedule III, which includes drugs such as Tylenol with codeine, testosterone and other anabolic steroids. This historic shift signals an acknowledgment of the promising medicinal value of cannabis.

The move comes in tandem with growing interest in the use of psilocybin, the active component in magic mushrooms, for treatment of depression, chronic pain and other conditions. In 2018 and 2019, the U.S. Food and Drug Administration granted a breakthrough therapy designation to psilocybin, meant to expedite drug development given that preliminary studies suggest it may have substantial therapeutic value over currently available therapies for treatment-resistant depression and major depressive disorder.

Both of these developments represent a dramatic change from long-standing federal policy around these substances that has historically criminalized their use and blocked or delayed research efforts into their therapeutic potential.